In today’s episode, MS Australia Deputy CEO, Dr Julia Morahan and Head of Research, Dr Tennille Luker report on and unpack ECTRIMS 2025 – the world’s largest MS treatment and research congress. The recent event attracted over 9000 international delegates and serves as a crucial platform for researchers, clinicians and healthcare providers to collaborate on, explore and advance novel life-changing research and treatment options for people with MS.

Julia and Tennille contextualise and share their perspectives on the most exciting developments, clinical trials, BTK (Bruton's tyrosine kinase) inhibitors, updated diagnostic criteria and more, presented at ECTRIMS 2025 under the theme of ‘a new era of precision’. The discussion also reflects on what these advances mean for the future of MS care and the people it impacts. Other focal points are the recently updated McDonald Diagnostic Criteria, research which could help provide even more personalised care and better predictions about disease progression, cutting-edge technologies, including AI and emergent therapies. Additionally, the episode spotlights paediatric MS, the exciting ‘late breaker’ sessions where some of the newest research findings are presented, and the patient community day.

Tune in for an in-depth look at how global experts are working together to shape the future of MS care and research.

For those who would like to watch the Patient Community Day sessions online, here is the link.